Biopharma Universe in ANZ

4 - 5 February 2026 | Australia

AUSTRALIA

Biologics

AdvanCell
Argenica Therapeutics
AbRegen
Aravax
Alexion
Amgen
Amplia Therapeutics Limited
Immuron
AstraZeneca
Anthrocell
CanCure
Clarity Pharmaceuticals
Gamma Vaccines
Glytherix Ltd
GPN Vaccines
HaemoLogiX
Immutep
Implicit Bioscience
Imugene
Imunexus Therapeutics
Kira Biotech
Myrio Therapeutics
Neuclone
Noxopharm
Opthea
Propanc Biopharma
Cambium Bio
Telix Pharmaceuticals
Teva Pharmaceuticals
Kazia Therapeutics
Lateral Pharma
Neuroscientific Biopharmaceuticals
Recce Pharmaceuticals

Government/Institutes / Academics / Research

University of Sydney – Charles Perkins Centre & School of Pharmacy
University of Melbourne – Biomedicine Discovery Institute (BDI)
Monash University – Monash Institute of Pharmaceutical Sciences (MIPS)
University of Queensland – Institute for Molecular Bioscience (IMB)
University of New South Wales (UNSW) – School of Biotechnology & Biomolecular Sciences
Macquarie University – ARC Centre for Translational Microbiome Research
University of Western Australia – Centre for Drug Design and Development
Australian National University (ANU) – John Curtin School of Medical Research
Griffith University – Institute for Glycomics
Flinders University – Centre for Cancer Biology
CSIRO
Walter and Eliza Hall Institute (WEHI)
Peter Doherty Institute for Infection & Immunity
Australian Centre for Vaccine Development (ACVD, UQ & QIMR)
QIMR Berghofer Medical Research Institute
Garvan Institute of Medical Research
South Australian Health & Medical Research Institute (SAHMRI)

Cell and Gene Therapy

Companies / Startups / Biotechs

AdAlta
Arovella Therapeutics
Avita Medical
Benitec Biopharma
Biosceptre
Carina Biotech
Cartherics
Celosia Therapeutics
Chimeric Therapeutics
CSL
Currus Biologics
Cynata Therapeutics
Cyteph
Cytomatrix
CytoPep
EnGeneIC
Facio BioTherapies
HealthRegen
ImmVirX
Innate Immunotherapeutics
Living Cell Technologies
Loxegen
Magellan Stem Cells
Mesoblast
Orthocell
Phoenix Eagle Company
Prescient Therapeutics
RheumaGen
S2N
Turquoise Biotechnologies
VivaZome Therapeutics

Research Institutes / Universities

CERA (Centre for Eye Research Australia)
Florey Institute
Garvan Institute
Harry Perkins Institute
Hudson Institute
Macquarie University
Monash University
Murdoch Children’s Research Institute
QIMR Berghofer
SAHMRI
University of Melbourne
University of Queensland
University of Sydney
UNSW Sydney
Victor Chang Cardiac Research Institute
WEHI

Regulatory / Funding Bodies

NHMRC – National Health & Medical Research Council
ARC – Australian Research Council
OGTR – Office of the Gene Technology Regulator
TGA – Therapeutic Goods Administration

RNA

Biopharma / Industry

Alnylam
Antisense Therapeutics
Benitec Biopharma
BioNTech
CSL
EnGeneIC
Gilead Sciences
ImmVirX
miReven
Moderna Australia
Novartis
Pfizer
PYC Therapeutics
RAGE Biotech
Sanofi
Seqirus (CSL)
Vaxine
Vaxxas
VivaZome Therapeutics

Institutes / Academics / Research

mRNA Victoria network
WEHI (Walter & Eliza Hall Institute)
QIMR Berghofer
Garvan Institute

Regulatory / Funding Bodies

NHMRC (National Health & Medical Research Council)
ARC (Australian Research Council)
TGA (Therapeutic Goods Administration)

NEW ZEALAND

Biologics

Biocell Corporation
BioOra
CuroNZ
Douglas Pharmaceuticals
AFT Pharmaceuticals
Pacific Edge
TheiaNova
Sementis
Helius Therapeutics

Cell and Gene Therapy

Companies / Startups / Biotechs

Living Cell Technologies
Loxegen

Research Institutes / Universities

Auckland Bioengineering Institute
Centre for Brain Research
Malaghan Institute of Medical Research
Maurice Wilkins Centre
University of Otago
University of Auckland
Liggins Institute

Regulatory / Funding Bodies

Callaghan Innovation
Health Research Council NZ
Medsafe

RNA

Biopharma / Industry

Amaroq Therapeutics

Institutes / Academics / Research

Malaghan Institute
University of Otago
University of Auckland
Vaccine Alliance Aotearoa New Zealand

Regulatory / Funding Bodies

Health Research Council NZ
Medsafe

CONTACT

Lara Santiago, Senior Portfolio Specialist

e: [email protected]

p: +63 9176 210686

Caterin Sanggita, Conference Producer

e: caterin.sanggita@imapac.com

p: +65 6983 6137

Ana Laxamana, Regional Business Development Lead

e: [email protected]

m: +65 6983 6132

Kaethe Fok, Sales Business Development Executive

e: [email protected]

p: +65 6990 1632

Share With Your Network